Friday Five – Parkinson’s Disease
Follow and join the conversation with #Parkinsons
According to the Parkinson’s Foundation, Parkinson’s disease is “a neurodegenerative disorder that affects predominately the dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra.” Symptoms can develop slowly over the years and may include tremors, slowness in movement, stiffness or rigidity, and balance problems. While there is not an exact known cause, scientists believe that genetics with a combination of environmental factors are what causes PD. 2023 has been a year of breakthrough research, bringing hope to the Parkinson’s Community, This week’s Friday Five includes details and updates regarding the latest research.
The Lancet Neurology
The Lancet Neurology (@TheLancetNeuro) is the leading journal in clinical neurology that publishes articles and reviews that advocate change in, or illuminate, clinical practice. In its most recent study: “Emerging evidence shows that α-synuclein seed amplification assays (SAAs) have the potential to differentiate people with Parkinson’s disease from healthy controls. Read the whole study complete with background, methods, findings, and interpretations.
In our May issue, Andrew Siderowf and colleagues used data from the @MichaelJFoxOrg PPMI cohort to assess whether alpha-synuclein seed amplification (aSyn-SAA) could effectively identify heterogeneity among people with and at-risk of Parkinson’s disease. https://t.co/f3HkkoS2Sw
— The Lancet Neurology (@TheLancetNeuro) April 13, 2023
NEW ONLINE, Udani Samarasekera reviews Still: A Michael J Fox Movie and learns more about the Michael J Fox Foundation for Parkinson’s Research. @MichaelJFoxOrg https://t.co/DXgVhGCcIO pic.twitter.com/lmDPpfmqvy
— The Lancet Neurology (@TheLancetNeuro) June 16, 2023
This webinar, moderated by Dr. James Beck, Chief Scientific Officer at the Parkinson’s Foundation, will review what those considering gene-based or cell-based therapy may expect in terms of symptom management and disease progression.
The Michael J Fox Foundation
BREAKING NEWS: Today, The Michael J. Fox Foundation has announced a significant breakthrough in the search for a Parkinson’s biomarker. This milestone opens a new chapter for research. Learn more: https://t.co/ZHbxrqwoYA pic.twitter.com/pOyEUx5XYj
— michaeljfox.org (@MichaelJFoxOrg) April 13, 2023
UCLA Health (@UCLAHealth) is among the most comprehensive and advanced health care systems in the world, providing the best patient experience with every patient, every encounter, every time. Five years ago, $25 million gift from Laurie and Steven Gordon, led the way to establishing their Commitment to Cure Parkinson’s Disease at the David Geffen School of Medicine. This article, ‘Competitive greatness’ drives 5 years of Parkinson’s research breakthroughs at UCLA, details the diverse research projects that gift has funded since 2018.
The University of California San Fransisco
UC San Francisco (@UCSF) is the leading university dedicated to advancing health worldwide through preeminent biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. Within our overarching advancing health worldwide mission, UCSF is devoted at every level to serving the public. Currently 26 Parkinson’s Disease clinical trails are in progress, with 12 open to eligible people. Click here for more details on these trails: Parkinson’s Disease clinical trials at UCSF.